Rapid Micro Biosystems reports Q3 EPS (26c), consensus (25c)

Reports Q3 revenue $7.83M, consensus $7.6M. Cash, cash equivalents, short-term investments, and restricted cash were approximately $42 million as of September 30. “Our Q3 results once again reflected strong and consistent execution across the business,” said Robert Spignesi, President and CEO. “We delivered record consumable revenue and double-digit service growth, and system placements were in line with our expectations. Recurring revenue increased more than 30% compared to the Q3 last year.”